Articles related to CLINICAL TRIALS

In a phase 3 trial involving 5,338 cisgender women in South Africa and Uganda, twice-yearly lenacapavir injections demonstrated complete prevention of HIV infection, significantly outperforming daily oral medication regimens.

A phase 3 clinical trial of buntanetap in early Parkinson’s disease patients demonstrated improvements in motor and cognitive functions, particularly in those with longer disease duration and postural instability.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

The addition of blinatumomab to consolidation chemotherapy in adults with MRD-negative B-cell precursor ALL demonstrated a significant improvement in overall survival. At 3 years, the overall survival rate was 85% in the blinatumomab group compared to 68% in the chemotherapy-only group.

In a trial of 2,736 participants, nirmatrelvir-ritonavir given as postexposure prophylaxis for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection compared to placebo among household contacts of COVID-19 patients.

Semaglutide treatment led to more frequent improvement and less frequent deterioration in NYHA functional class compared to placebo in patients with obesity-related HFpEF over 52 weeks.